This $259,461 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to investigate the mechanisms driving carbapenem resistance in non-carbapenemase producing Klebsiella pneumoniae (NCP-KPN) infections. The award will fund two key objectives:
-
Characterizing the genomic factors associated with discordant carbapenem susceptibility in a global collection of NCP-KPN isolates, and evaluating the emergence of resistance to carbapenems and beta-lactam/beta-lactamase inhibitor combinations using an in vitro model.
-
Assessing the clinical impact of NCP-KPN infections, including differences in mortality, relapse, and resistance emergence across isolates stratified by meropenem susceptibility and resistance mechanisms.
The findings from this research will help inform optimal antibiotic selection for treating NCP-KPN infections and guide the design of future prospective clinical trials. The awardee, The Methodist Hospital Research Institute, has extensive experience conducting infectious disease and medical countermeasure research as a subcontractor on federal contracts and grants.
Generated 3/18/25, 4:46 AM